focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Cabinet minister warns of "concerning situation" as Omicron spreads

Sat, 11th Dec 2021 09:29

(Alliance News) - A booster dose sees the risk of symptomatic infection with the Omicron variant "significantly reduced", according to health officials who have urged all those eligible to make sure they get their third jab.

It comes as the experts warned the new variant could become the dominant strain in the UK by mid-December, with a Cabinet minister saying everything is being kept "under review" in terms of measures to tackle the spread.

Analysis by the UK Health Security Agency found that the AstraZeneca PLC and Pfizer Inc-BioNTech SE vaccines provided "much lower" levels of protection against symptomatic infection with Omicron compared to Delta.

But the preliminary data, which looked at 581 people with confirmed Omicron, suggested effectiveness seemed to "increase considerably" in the early period after a booster dose, giving around 70% to 75% protection against symptomatic infection.

The findings come as daily Covid-19 cases reached their highest level in almost a year and the UKHSA predicted that, if current trends continue, the UK will exceed one million infections by the end of the month.

Cabinet minister Michael Gove warned of a "deeply concerning situation" after holding a Cobra meeting on Friday afternoon to discuss the latest data and the co-ordinated response across the four nations.

The government said, as of 9 am on Friday, there had been a further 58,194 lab-confirmed Covid-19 cases in the UK.

The last time a higher daily figure was reported was on January 9, when 59,937 cases were recorded.

An additional 448 confirmed cases of the Omicron variant have been reported across the UK, bringing the total number to 1,265.

Mary Ramsay, head of immunisation at the UKHSA, said while their early data should be treated with caution, it indicates that "a few months after the second jab, there is a greater risk of catching the Omicron variant compared to Delta strain".

She added: "The data suggest this risk is significantly reduced following a booster vaccine, so I urge everyone to take up their booster when eligible."

Speaking to broadcasters, Gove said the Omicron variant is doubling every two to three days in England "and possibly even faster in Scotland".

He added that 30% of reported cases in London are the new variant, and warned that evidence suggests Omicron is "more likely" than past Covid variants to "potentially" lead to hospital admissions among the fully vaccinated.

Scotland's First Minister Nicola Sturgeon has warned of the possibility of a "tsunami of infections" from the new variant – and said she could not rule out more restrictions north of the border as a result.

But No 10 maintained that there were "no plans" to go further with measures in England, amid reports that proposals are being drawn up for a Plan C, featuring even tougher rules.

Gove said the current approach being taken is "proportionate", but acknowledged that "we absolutely do need to keep everything under review".

He said: "Action is absolutely required and, as new data comes in, we will consider what action we do require to take in the face of that data."

The Guardian reported that UK Health Secretary Sajid Javid had been given a presentation from the UKHSA earlier this week warning that even if Omicron leads to less serious disease than Delta, it still risks overwhelming the NHS with 5,000 people admitted to hospital a day.

It said the leaked advice said "stringent action" would be needed on or before December 18 if the variant's doubling time stays at 2.5 days, although the newspaper added that what such restrictions might entail were not set out other than to say measures that would bring the R number – representing the average number of people each Covid-19 positive person goes on to infect – below 1.

Professor Neil Ferguson, from Imperial College London, whose data was instrumental to the UK going into lockdown in March 2020, told The Guardian that projections suggest Omicron could "very substantially overwhelm the NHS, getting up to peak levels of admissions of 10,000 people per day".

He said such a figure could be reached "sometime in January" but added that it was based on assumptions around the variant's ability to get around existing protection, and the premise that it is similar to Delta in terms of the severity of disease it causes – something that is not yet known.

He said: "Even the best-case scenarios involve several-fold more admissions per day than we're getting at the moment – we are at about 700 right now."

New guidance expected to come into force from Wednesday will see care home residents allowed only three visitors and one essential care worker, as part of new measures to protect the sector from the spread of the new variant.

The Department of Health & Social Care said the move was "in order to balance the current Covid-19 risk and the need to keep people safe in line with clinical advice".

From Friday, in England the legal requirement to wear masks was extended to more indoor spaces including museums, galleries and community centres.

There will be a return to working from home guidance from Monday, and mandatory Covid passports for large venues from Wednesday.

The new regulations will be put to a debate and vote in the Commons next week – and with Labour's support they are certain to be approved despite the prospect of a large Conservative revolt.

Asked about the expected Tory rebellion, Gove said he is "confident" people will examine the proposals "seriously, soberly and thoughtfully", adding: "And I'm also confident people will conclude that, on balance, it is right to act."

By PA Reporters

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.